Kill and spread the word: Stimulation of antitumor immune responses in the context of radiotherapy

Immunotherapy

Volumn 6, Issue 5, 2014, Pages 597-610

  Gaipl, Udo S ^a   Multhoff, Gabriele ^b   Scheithauer, Heike ^c   Lauber, Kirsten ^c   Hehlgans, Stefanie ^d   Frey, Benjamin ^a   Rödel, Franz ^d  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

Abscopal effect; Annexin A5; Dendritic cell; Heat shock protein 70; High mobility group box protein 1; Immunogenic tumor cell death; Immunotherapy; Radiotherapy; Survivin; Vaccination

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA2B INTERFERON; CANCER VACCINE; CELECOXIB; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; GATAPARSEN; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; MRNA VACCINE; PEPTIDE VACCINE; PNEUMOCOCCUS VACCINE; PROTEIN P53; PROTEIN P53 PLUS SURVIVIN PLUS TELOMERASE REVERSE TRANSCRIPTASE; SEPANTRONIUM BROMIDE; SURVIVIN; SURVIVIN 2B VACCINE; SURVIVIN 2B80-88 PEPTIDE VACCINE; SURVIVIN PLUS TELOMERASE REVERSE TRANSCRIPTASE; SURVIVIN VACCINE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; HMGB1 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; COLORECTAL CANCER; DENDRITIC CELL; DNA DAMAGE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; KIDNEY CARCINOMA; MELANOMA; MOUTH CANCER; MYELOMA; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINATION; X IRRADIATION; CELLULAR IMMUNITY; IMMUNOLOGY; NEOPLASMS; RADIATION RESPONSE; T LYMPHOCYTE; X RAY;

ADENOSINE TRIPHOSPHATE; DENDRITIC CELLS; DNA DAMAGE; HMGB1 PROTEIN; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; KILLER CELLS, NATURAL; NEOPLASMS; RADIOTHERAPY; T-LYMPHOCYTES; X-RAYS;

EID: 84902076277     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.38     Document Type: Review

References (121)

1. Frey B, Rubner Y, Kulzer L et al. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol. Immunother. 63(1), 29-36 (2013).
2. Vesely MD, Schreiber RD. Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy. Ann. NY Acad. Sci. 1284, 1-5 (2013).
3. Vajdic CM, Van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int. J. Cancer 125(8), 1747-1754 (2009).
4. Tesniere A, Panaretakis T, Kepp O et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15(1), 3-12 (2008).
5. Chaurio RA, Janko C, Munoz LE, Frey B, Herrmann M, Gaipl US. Phospholipids: Key players in apoptosis and immune regulation. Molecules 14(12), 4892-4914 (2009).
6. Kolb R, Liu GH, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: A double-edged sword. Protein Cell doi:10.1007/s13238-013-0001-4 (2014) (Epub ahead of print).
7. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Sem. Immunol. 8(5), 271-280 (1996).
8. Bianchi ME. DAMPs, PAMPs and alarmins: All we need to know about danger. J. Leukoc. Biol. 81(1), 1-5 (2007).
9. Frey B, Stache C, Rubner Y et al. Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential. J. Immunotoxicol. 9(3), 301-313 (2012).
10. Frey B, Rubner Y, Wunderlich R et al. Induction of abscopal anti-Tumor immunity and immunogenic tumor cell death by ionizing irradiation-implications for cancer therapies. Curr. Med. Chem. 19(12), 1751-1764 (2012).
11. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418(6894), 191-195 (2002).
12. Park JS, Gamboni-Robertson F, He Q et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell. Physiol. 290(3), C917-924 (2006).
13. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191(3), 423-434 (2000).
14. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol. 81(1), 84-91 (2007).
15. Schildkopf P, Frey B, Mantel F et al. Application of hyperthermia in addition to ionizing irradiation fosters necrotic cell death and HMGB1 release of colorectal tumor cells. Biochem. Biophys. Res. Commun. 391(1), 1014-1020 (2010).
16. Li W, Wu K, Zhao E et al. HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of colon cancer after resection. Biochem. Biophys. Res. Commun. 436(2), 156-161 (2013).
17. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13(9), 1050-1059 (2007).
18. Elliott MR, Chekeni FB, Trampont PC et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461(7261), 282-286 (2009).
19. Aymeric L, Apetoh L, Ghiringhelli F et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 70(3), 855-858 (2010).
20. Ghiringhelli F, Apetoh L, Tesniere A et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1betadependent adaptive immunity against tumors. Nat. Med. 15(10), 1170-1178 (2009).
21. Ma Y, Adjemian S, Mattarollo SR et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38(4), 729-741 (2013).
22. Trabanelli S, Ocadlikova D, Gulinelli S et al. Extracellular ATP exerts opposite effects on activated and regulatory CD4+ T cells via purinergic P2 receptor activation. J. Immunol. 189(3), 1303-1310 (2012).
23. Denagel DC, Pierce SK. A case for chaperones in antigen processing. Immunol Today 13(3), 86-89 (1992).
24. Garrido C, Fromentin A, Bonnotte B et al. Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res. 58, 5495-5499 (1998).
25. Jäättelä M. Heat shock proteins as cellular lifeguards. Ann. Med. 31, 261-271 (1999).
26. Radons J, Multhoff G. Immunostimulatory functions of membrane-bound and exported heat shock protein 70. Exerc. Immunol. Rev. 11, 17-33 (2005).
27. Multhoff G, Botzler C, Wiesnet M et al. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int. J. Cancer 61, 272-279 (1995).
28. Shin BK, Wang H, Yim AM et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J. Biol. Chem. 278(9), 7607-7616 (2003).
29. Multhoff G, Pockley AG, Streffer C, Gaipl US. Dual role of heat shock proteins (HSPs) in anti-Tumor immunity. Curr. Mol. Med. 12(9), 1174-1182 (2012).
30. Multhoff G, Pfister K, Gehrmann M et al. A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones 6, 337-344 (2001).
31. Pfister K, Radons J, Busch R et al. Patient survival by Hsp70 membrane phenotype: Association with different routes of metastasis. Cancer 110(4), 926-935 (2007).
32. Gehrmann M, Liebisch G, Schmitz G et al. Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS ONE 3(4), e1925 (2008).
33. Schilling D, Gehrmann M, Steinem C et al. Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells. FASEB J. 23(8), 2467-2477 (2009).
34. Rubner Y, Wunderlich R, Ruhle PF et al. How does ionizing irradiation contribute to the induction of anti-Tumor immunity? Front. Oncol. 2, 75 (2012).
35. Schutters K, Reutelingsperger C. Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis 15(9), 1072-1082 (2010).
36. Bondanza A, Zimmermann VS, Rovere-Querini P et al. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J. Exp. Med. 200(9), 1157-1165 (2004).
37. Frey B, Munoz LE, Pausch F et al. The immune reaction against allogeneic necrotic cells is reduced in Annexin A5 knock out mice whose macrophages display an antiinflammatory phenotype. J. Cell. Mol. Med. 13(7), 1391-1399 (2009).
38. Frey B, Schildkopf P, Rodel F et al. AnnexinA5 renders dead tumor cells immunogenic-implications for multimodal cancer therapies. J. Immunotoxicol. 6(4), 209-216 (2009).
39. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 47, 187-376 (1989).
40. Ljunggren HG, Karre K. In search of the 'missing self ': MHC molecules and NK cell recognition. Immunol. Today 11, 237-244 (1990).
41. Gross C, Koelch W, Demaio A, Arispe N, Multhoff G. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J. Biol. Chem. 278(42), 41173-41181 (2003).
42. Gross C, Schmidt-Wolf IG, Nagaraj S et al. Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. Cell Stress Chaperones 8, 348-360 (2003).
43. Gastpar R, Gehrmann M, Bausero MA et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 65, 5238-5247 (2005).
44. Botzler C, Li G, Issels RD, Multhoff G. Definition of extracellular localized epitopes of Hsp70 involved in an NK immune response. Cell Stress Chaperones 3, 6-11 (1998).
45. Multhoff G, Mizzen L, Winchester CC et al. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Exp. Hematol. 27, 1627-1636 (1999).
46. Gross C, Hansch D, Gastpar R, Multhoff G. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol. Chem. 384, 267-279 (2003).
47. Chen X, Tao Q, Yu H, Zhang L, Cao X. Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity. Immunol. Lett. 84(2), 81-87 (2002).
48. Pilla L, Squarcina P, Coppa J et al. Natural killer and NKLike T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. Cancer Res. 65, 3942-3949 (2005).
49. Todryk SM, Gough MJ, Pockley AG. Facets of heat shock protein 70 show immunotherapeutic potential. Immunology 110, 1-9 (2003).
50. Schildkopf P, Frey B, Ott OJ et al. Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. Radiother. Oncol. 101(1), 109-115 (2011).
51. Bausero MA, Gastpar R, Multhoff G, Asea A. Alternative mechanism by which IFN-gamma enhances tumor recognition: Active release of heat shock protein 72. J. Immunol. 175, 2900-2912 (2005).
52. Lancaster GI, Febbraio MA. Exosome-dependent trafficking of HSP70: A novel secretory pathway for cellular stress proteins. J. Biol. Chem. 280(24), 23349-23355 (2005).
53. Torigoe T, Tamura Y, Sato N. Heat shock proteins and immunity: Application of hyperthermia for immunomodulation. Int. J. Hyperthermia 25(8), 610-616 (2009).
54. Liu LL, Smith MJ, Sun BS, Wang GJ, Redmond HP, Wang JH. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model. Ann. Surg. Oncol. 16(5), 1403-1411 (2009).
55. Gupta A, Probst HC, Vuong V et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J. Immunol. 189(2), 558-566 (2012).
56. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174(12), 7516-7523 (2005).
57. Diamond MS, Kinder M, Matsushita H et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208(10), 1989-2003 (2011).
58. Orth M, Lauber K, Niyazi M et al. Current concepts in clinical radiation oncology. Radiat. Environ. Biophys. 53(1), 1-29 (2014).
59. Keisari Y, Hochman I, Confino H, Korenstein R, Kelson I. Activation of local and systemic anti-Tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments. Cancer Immunol. Immunother. 63(1), 1-9 (2013).
60. Takeshima T, Chamoto K, Wakita D et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: Its potentiation by combination with Th1 cell therapy. Cancer Res. 70(7), 2697-2706 (2010).
61. Weng D, Song B, Koido S, Calderwood SK, Gong J. Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation. J. Immunol. 191(2), 755-763 (2013).
62. Demaria S, Ng B, Devitt ML et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 862-870 (2004).
63. Dewan MZ, Galloway AE, Kawashima N et al. Fractionated but not single-dose radiotherapy induces an immunemediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15(17), 5379-5388 (2009).
64. Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J. Exp. Med. 210 (11), 2435 (2013).
65. Balermpas P, Michel Y, Wangenblast J et al. Tumourinfiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br. J. Cancer 110, 501-509 (2013).
66. Hald SM, Bremnes RM, Al-Shibli K et al. CD4/CD8 coexpression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy. Lung Cancer 80(2), 209-215 (2013).
67. Mahmoud SM, Paish EC, Powe DG et al. Tumorinfiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29(15), 1949-1955 (2011).
68. Schaue D, Comin-Anduix B, Ribas A et al. T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin. Cancer Res. 14(15), 4883-4890 (2008).
69. Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366(10), 925-931 (2012).
70. Konoeda K. Therapeutic efficacy of pre-operative radiotherapy on breast carcinoma: In special reference to its abscopal effect on metastatic lymph-nodes. Nihon Gan Chiryo Gakkai Shi 25(6), 1204-1214 (1990).
71. Lauber K, Ernst A, Orth M, Herrmann M, Belka C. Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front. Oncol. 2, 116 (2012).
72. Haviland JS, Owen JR, Dewar JA et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 14(11), 1086-1094 (2013).
73. Darby S, Mcgale P, Correa C et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-Analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804), 1707-1716 (2011).
74. Hehlgans S, Petraki C, Reichert S, Cordes N, Rodel C, Rodel F. Double targeting of Survivin and XIAP radiosensitizes 3D grown human colorectal tumor cells and decreases migration. Radiother. Oncol. 108(1), 32-39 (2013).
75. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 8(1), 61-70 (2008).
76. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 430(2), 199-205 (2010).
77. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J. Biol. Chem. 273(18), 11177-11182 (1998).
78. Velculescu VE, Madden SL, Zhang L et al. Analysis of human transcriptomes. Nat. Genet. 23(4), 387-388 (1999).
79. Groner B, Weiss A. Targeting survivin in cancer: Novel drug development approaches. BioDrugs 28(1), 27-39 (2014).
80. Rodel F, Sprenger T, Kaina B et al. Survivin as a prognostic/ predictive marker and molecular target in cancer therapy. Curr. Med. Chem. 19(22), 3679-3688 (2012).
81. Altieri DC. Targeting survivin in cancer. Cancer Lett. 332(2), 225-228 (2013).
82. Khan S, Aspe JR, Asumen MG et al. Extracellular, cellpermeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br. J. Cancer 100(7), 1073-1086 (2009).
83. Khan S, Jutzy JM, Aspe JR, Mcgregor DW, Neidigh JW, Wall NR. Survivin is released from cancer cells via exosomes. Apoptosis 16(1), 1-12 (2011).
84. Khan S, Jutzy JM, Valenzuela MM et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS ONE 7(10), e46737 (2012).
85. Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-Associated antigen survivin. Clin. Cancer Res. 13(20), 5991-5994 (2007).
86. Andersen MH, Thor SP. Survivin-A universal tumor antigen. Histol. Histopathol. 17(2), 669-675 (2002).
87. Reuschenbach M, Von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol. Immunother. 58(10), 1535-1544 (2009).
88. Rohayem J, Diestelkoetter P, Weigle B et al. Antibody response to the tumor-Associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 60(7), 1815-1817 (2000).
89. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61(3), 869-872 (2001).
90. Sorensen RB, Svane IM, Straten PT, Andersen MH. A survivin specific T-cell clone from a breast cancer patient display universal tumor cell lysis. Cancer Biol. Ther. 7(12), 1885-1887 (2008).
91. Coughlin CM, Fleming MD, Carroll RG et al. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J. Clin. Oncol. 24(36), 5725-5734 (2006).
92. Decker WK, Qiu J, Farhangfar F, Hester JH, Altieri DC, Lin AY. A retrogen plasmid-based vaccine generates high titer antibody responses against the autologous cancer antigen survivin and demonstrates anti-Tumor efficacy. Cancer Lett. 237(1), 45-55 (2006).
93. Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol. Oncol. 115(1), 112-120 (2009).
94. Williams EL, Dunn SN, James S et al. Immunomodulatory monoclonal antibodies combined with Peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin. Cancer Res. 19(13), 3545-3555 (2013).
95. Wang YQ, Zhang HH, Liu CL et al. Enhancement of survivin-specific anti-Tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. Int. Immunopharmacol. 17(1), 9-17 (2013).
96. Sher YP, Liu SJ, Chang CM et al. Cancer-Targeted BikDD gene therapy elicits protective antitumor immunity against lung cancer. Mol. Cancer Ther. 10(4), 637-647 (2011).
97. Xiao LL, Wu YM, Qian J et al. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus. Cancer Biol. Ther 10(3), 242-250 (2010).
98. Ciesielski MJ, Ahluwalia MS, Munich SA et al. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol. Immunother. 59(8), 1211-1221 (2010).
99. Lladser A, Ljungberg K, Tufvesson H et al. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol. Immunother. 59(1), 81-92 (2010).
100. Otto K, Andersen MH, Eggert A et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 23(7), 884-889 (2005).
101. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol. Immunother. 55(10), 1294-1298 (2006).
102. Rosenberg SA. Development of effective immunotherapy for the treatment of patients with cancer. J. Am. Coll. Surg. (5), 685-696 (2004).
103. Rittig SM, Haentschel M, Weimer KJ et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol. Ther. 19(5), 990-999 (2011).
104. Kameshima H, Tsuruma T, Kutomi G et al. Immunotherapeutic benefit of alpha-interferon (IFNalpha) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci. 104(1), 124-129 (2013).
105. Berntsen A, Trepiakas R, Wenandy L et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: A clinical Phase 1/2 trial. J. Immunother. 31(8), 771-780 (2008).
106. Ellebaek E, Engell-Noerregaard L, Iversen TZ et al. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: Results from a Phase II trial. Cancer Immunol. Immunother. 61(10), 1791-1804 (2012).
107. Rapoport AP, Aqui NA, Stadtmauer EA et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 117(3), 788-797 (2011).
108. Sioud M, Saeboe-Larssen S, Hetland TE, Kaern J, Mobergslien A, Kvalheim G. Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients. Int. J. Oncol. 43(1), 280-288 (2013).
109. Soleimani A, Berntsen A, Svane IM, Pedersen AE. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand. J. Immunol. 70(5), 481-489 (2009).
110. Miyazaki A, Kobayashi J, Torigoe T et al. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci. 102(2), 324-329 (2011).
111. Trepiakas R, Berntsen A, Hadrup SR et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: Results from a Phase I/II trial. Cytotherapy 12(6), 721-734 (2010).
112. Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-Apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Trans. Med. 2(1), 19 (2004).
113. Becker JC, Andersen MH, Hofmeister-Muller V et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: A Phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol. Immunother. 61(11), 2091-2103 (2012).
114. Filipazzi P, Pilla L, Mariani L et al. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin. Cancer Res. 18(23), 6485-6496 (2012).
115. Tanaka M, Butler MO, Ansen S et al. Induction of HLADP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell. Clin. Cancer Res. 17(16), 5392-5401 (2011).
116. Giaccone G, Zatloukal P, Roubec J et al. Multicenter Phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-smallcell lung cancer. J. Clin. Oncol. 27(27), 4481-4486 (2009).
117. Satoh T, Okamoto I, Miyazaki M et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin. Cancer Res. 15(11), 3872-3880 (2009).
118. Talbot DC, Ranson M, Davies J et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: A proof-of-concept, first-in-human dose study. Clin. Cancer Res. 16(24), 6150-6158 (2010).
119. Tanioka M, Nokihara H, Yamamoto N et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 68(2), 505-511 (2011).
120. Tolcher AW, Mita A, Lewis LD et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J. Clin. Oncol. 26(32), 5198-5203 (2008).
121. Rodel F, Frey B, Multhoff G, Gaipl U. Contribution of the immune system to bystander and non-Targeted effects of ionizing radiation. Cancer Lett. doi:10.1016/j. canlet.2013.09.015 (2013) (Epub ahead of print).